Market indices fall below 200-day moving averages as software stocks sell off; Paycom, Ascendis, and TGTX highlighted as potential opportunities
Summary
Speakers analyze broad market weakness with the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average trading below their 200-day moving averages. The sell-off was driven heavily by software stocks, particularly Salesforce, while chip stocks like those in the SMH ETF showed relative strength. Analysts identified Paycom (PAYC) as a resilient enterprise software stock holding above its 50-day moving average. Biotech stocks Ascendis Pharma (ASND) and TG Therapeutics (TGTX) were highlighted for strong fundamentals and technical setups. NVIDIA (NVDA) earnings were noted as positive despite recent declines, with focus shifting to leadership transition and China shipments.
Episode sections
- 0:09 – 9:33
Market Index Technicals and Breadth
Speakers analyze major US equity indices showing broad weakness, with the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average all trading below their 200-day moving averages. The Russell 2000 also made fresh lows, indicating significant selling pressure across market caps, though the Nasdaq closed off its intraday lows.
- 9:33 – 17:12
Sector Performance and Software Weakness
The discussion highlights severe selling in software stocks, led by Salesforce's 9% decline, which dragged down the Dow. The IGV (iShares Global Software ETF) underperformed chip stocks (SMH) by a wide margin, while financials and healthcare sectors also lagged due to yield movements and regulatory fears.
- 17:12 – 20:03
Paycom (PAYC) Technical Strength
Paycom is identified as a standout performer in the enterprise software sector, holding above its 50-day moving average despite the sector-wide sell-off. The speaker notes the stock is in a 'buy zone' following a volatile earnings reaction, citing strong institutional quality and leadership in workforce management software.
- 20:03 – 22:39
Ascendis Pharma (ASND) Biotech Analysis
Ascendis Pharma is presented as a profitable biotech with a unique 'transcon' drug delivery technology, focusing on oncology and pediatric growth hormone deficiency. The stock is described as having consistent top-line growth, strong mutual fund sponsorship, and a double-bottom base formation on the weekly chart.
- 22:39 – 25:06
TG Therapeutics (TGTX) Pullback Dynamics
TG Therapeutics is highlighted for its blockbuster drug Briumvi, approaching $1 billion in annual revenue for multiple sclerosis treatment. The stock is noted for an orderly, low-volume pullback following a high-volume earnings breakout, potentially offering an entry point near its 21-day moving average.
- 25:06 – 28:53
NVIDIA (NVDA) Earnings and Leadership Transition
NVIDIA reported earnings beating top and bottom lines with a positive outlook, despite recent declines due to AI fears and CEO exit news. The upcoming conference call is expected to be highly scrutinized, particularly regarding China chip shipments and the transition to interim CEO Colette Kress.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| NVIDIANVDA | equity | neutral | We have an important uh earnings report from NVIDIA, of course, uh after after the close, and that will probably dictate what uh what the action uh tomorrow will will hold. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
The Nasdaq Composite closed down about three-quarters of a percent on the day, November 17, 2026.
Alyssa Koram ·1:13
How to verify: Check historical closing data for the Nasdaq Composite Index (IXIC) for November 17, 2026, via Yahoo Finance or Bloomberg. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
The S&P 500 (SPY) breached its 200-day moving average on November 17, 2026.
Alyssa Koram ·1:33
How to verify: Compare the closing price of SPY on November 17, 2026, against its 200-day simple moving average calculated from historical price data. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
The Dow Jones Industrial Average closed at 57,61, below its 200-day moving average of 57,77.
Alyssa Koram ·9:33
How to verify: Verify the closing price of the DJI on November 17, 2026, and calculate its 200-day moving average using historical data. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Salesforce (CRM) declined 9% intraday on November 17, 2026.
Unidentified speaker (speaker_1) ·10:55
How to verify: Check intraday high and low prices for Salesforce (CRM) on November 17, 2026, to calculate the percentage decline from the high. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
The iShares Global Software ETF (IGV) fell 3.3% on November 17, 2026.
Unidentified speaker (speaker_1) ·10:35
How to verify: Check the closing price of IGV on November 17, 2026, against its previous close to verify the percentage decline. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourcePaycom (PAYC) shares were down 2.7% on November 17, 2026.
Alyssa Koram ·17:31
How to verify: Check the closing price of Paycom (PAYC) on November 17, 2026, against its previous close. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceAscendis Pharma (ASND) has a market capitalization of $16-17 billion.
Unidentified speaker (speaker_1) ·20:39
How to verify: Check the market capitalization of Ascendis Pharma (ASND) as of November 17, 2026, via financial data providers like Bloomberg or Reuters. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceTG Therapeutics' drug Briumvi is approaching $1 billion in annual revenue.
Unidentified speaker (speaker_1) ·23:09
How to verify: Review TG Therapeutics' (TGTX) recent SEC filings (10-K or 10-Q) or earnings reports for revenue breakdowns of Briumvi. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceNVIDIA (NVDA) stock rose about 3% in its first earnings report post-Jensen Huang's exit.
Alyssa Koram ·25:35
How to verify: Check NVIDIA's stock price movement on November 17, 2026, following the after-hours earnings release. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceOctober retail sales (excluding autos) were up 0.6%, beating the 0.4% expectation.
Unidentified speaker (speaker_1) ·15:11
How to verify: Check the US Census Bureau's October 2026 Retail Sales report for the headline and ex-auto figures. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Do your own research
- Verify current price action of SPY, QQQ, and DIA relative to their 200-day moving averages using a financial data provider.
- Check Salesforce (CRM) earnings report and guidance for reasons behind the 9% decline.
- Review Paycom (PAYC) recent earnings call transcript for details on workforce management software demand.
- Analyze Ascendis Pharma (ASND) pipeline for 'transcon' drug delivery technology and oncology/pediatric growth hormone indications.
- Confirm TG Therapeutics (TGTX) Briumvi sales data and regulatory status for multiple sclerosis treatment.
- Monitor NVIDIA (NVDA) upcoming conference call for updates on China chip shipments and interim CEO Colette Kress transition.
Full transcriptexpand
- 0:09
- Unidentified speaker (UNKNOWN): Good
- 0:10
- Alyssa Koram: afternoon, everyone. Welcome to Stock Market Today. It's Alyssa Koram here. It is Tuesday, November 17th, and some key levels that we need to discuss for the major indexes selling today. Where does that leave the overall trend and where we can could go from here? Joining me now to discuss more is
- 0:29
- Alyssa Koram: my colleague, Ken Shreve. Ken, what do you have for us today?
- 0:33
- Unidentified speaker (speaker_1): Yeah, this was a day of key levels for some of the indexes, uh, Allie. Uh but yeah, tough day for software stocks, uh, particularly in the Dow Jones uh, but not for Paycom. Uh, I want to take a look at Paycom P-A-Y-C. P A Y C. Um, that had a pretty good day. And I want to take a look at a couple of
- 0:53
- Unidentified speaker (speaker_1): biotech stocks that are flexing their muscle in this market. I want to take a look at a name that we haven't uh looked at, I don't think, uh ever, as a matter of fact. Uh Ascendus, uh S N D uh is the ticker there. And then uh TG Therapeutics, T TGTX. G T X.
- 1:13
- Alyssa Koram: All right. We'll take a look at those stocks. But first, a closer look at the major indexes. Here's the NASDAQ composite. It did finish off lows, but still down about three quarters of a percent on the day and intraday undercutting the low from that terrible down day on the 5th of November. Meanwhile, the S
- 1:33
- Alyssa Koram: SP P 500 down a little over 1% on the day. And you can see the SPY ETF here. Ken. We got a breach of that key 200-day moving average. So the SP now joining the Nasdaq composite below that key level of support. And then let's check out blue chips.
- 1:53
- Alyssa Koram: Here is the Dow. That was down about 1.6%
- 1:57
- Alyssa Koram: on the day, also now below its 200-day moving average and small. caps. Here's the Russell 2000 making a fresh low down one and a half percent. So undercutting the lows from the last couple of weeks here, Ken. So we're continuing to see a lot of weakness out there.
- 2:17
- Alyssa Koram: How should investors be thinking about these new lows for the market?
- 2:24
- Unidentified speaker (speaker_1): Well, uh, you know, I mean, on the on the one. on the hand you've got uh a good shakeout going on in the uh in the Nasdaq right now. So you do have some sellers getting shaken out. And you do you have some sellers getting shaken out uh today when you had that uh that low from uh well probably a couple of weeks ago at this point uh getting uh
- 2:44
- Unidentified speaker (speaker_1): getting undercut cut uh today. Um yeah you can see that low uh right there got undercut and uh you know and then the Nasdaq made a pretty key test of a round number today of uh of twenty four thousand and uh and closed uh off its uh off its uh off its lows uh today. So uh will
- 3:04
- Unidentified speaker (speaker_1): this uh will this be a bottom and will this uh eventually, you know, be the uh the the that the the area where the Nasdaq uh starts to to rally and maybe we see the first day of a rally attempt and and then maybe a a new rally that starts from here we'll have to we'll have to see. But uh there was uh there was a a really good uh shakeout this morning. I mean at its low
- 3:24
- Unidentified speaker (speaker_1): today the Nasdaq uh did pull back uh about thirteen and a half percent off its uh off off its high from you know that twenty seven thousand seven hundred uh high that it uh hit so you know 13.5% thirteen and a half percent off its high. We've uh we've come down you know, quite quite a bit. That's been a pretty pretty sharp uh pullback here. So
- 3:44
- Unidentified speaker (speaker_1): a nice uh another undercut uh today, a nice uh test of that uh twenty four thousand level. So uh we're getting a good shakeout in the uh in the Nasdaq uh today a nice uh a nice uh a nice not not so much selling in the chip sector today it was more uh more in the in the software uh sector.
- 4:04
- Unidentified speaker (speaker_1): So uh we don't know if uh if the selling has run its uh course. Uh we have an important uh earnings report from NVIDIA, of course, uh after after the close, and that will probably dictate what uh what the action uh tomorrow will will hold. But uh you know, I will We'll say just uh you know uh a uh uh good some more selling in the
- 4:24
- Unidentified speaker (speaker_1): NASDAQ uh today and some more sellers getting shaken out of the
- 4:26
- Unidentified speaker (UNKNOWN): city.
- 4:27
- Unidentified speaker (speaker_1): this uh market. It was encouraging to see the Nasdaq uh close off its uh off its low today. So that was a positive uh as well. But you know, not not much great action in the market today. The breadth on the Nasdaq was uh pretty negative uh all day. Three to one uh three to one uh you know decliners uh
- 4:46
- Unidentified speaker (speaker_1): beating uh beating advancers and a little worse on the on the New York stock. exchange today.
- 4:52
- Alyssa Koram: Yeah. All right. So the uh move off lows, uh the silver lining here, Ken, for the Nasdaq, but a couple of other technical levels to point out, uh to reiterate what you were saying about twenty four thousand. That is where the Nasdaq got support, uh, which if you draw
- 5:12
- Alyssa Koram: back, that was a a breakout area in the April time frame. So I feel like to the downside, this becomes our new level. Can we find some sort of floor of support? Will support hold here? And now we have to look for a rally attempt. So can we get some momentum to the upside? Can the Nasdaq
- 5:32
- Alyssa Koram: get back to that 200 day? And senior market strategist at IUBD, Mike Webster, has caught. cautioned in recent weeks that when you're below the 200 day line, you need to lean more cautious, more bearish. That's not to say that we can't get successful follow-through days underneath the
- 5:52
- Alyssa Koram: 200 day line, but
- 5:54
- Unidentified speaker (UNKNOWN): you
- 5:54
- Alyssa Koram: don't want to try to guess the bottom either, right? Um, I guess some might look at the reversal today as a line in the sand to to manage risk against. But it seems like with the weakness elsewhere, like with the S P 500 breaching its 200 day line
- 6:14
- Alyssa Koram: as well, you know, also coming off low. So testing that level by the close, even with that intraday breach, it just seems like we are seeing net selling. uh by and large at this time, Ken, even if we are seeing pockets of strength underneath the surface.
- 6:32
- Unidentified speaker (speaker_1): Yeah, yeah. I mean the SP, you know, it it to its credit, it did make a stand at its uh 200-day moving average. Uh like the NASDAQ, it uh it did uh close off lows uh a little bit. Uh the Nasdaq, you know, Nasdaq at least closed in the middle half of its range. It may it may have even closed uh in in slightly. the upper upper half of
- 6:52
- Unidentified speaker (speaker_1): its range, at least in the middle of its range. S P five hundred looked like it was kind of in the bottom half, but it did close, you know, right at the uh at the two hundred day line and uh and made an effort to to find support here. Uh like the Nasdaq, uh it also had an undercut of uh of that low from uh a couple uh a couple of weeks ago and uh and
- 7:12
- Unidentified speaker (speaker_1): again it closed right at its uh its 200-day uh moving average. So uh you know, very similar price action to the uh NASDAQ. Again, the breadth was a little more negative on the NYSE today. It was about four to one uh negative uh with uh losers uh beating winners. Uh so again, a little you know, a shakeout in the
- 7:32
- Unidentified speaker (speaker_1): SP 500 today, uh support at the 200-day moving average. Uh again, we're gonna just kind of gonna keep an eye out for day one of a of a rally attempt. It could happen uh tomorrow. Maybe we'll get uh maybe we'll get a nice uh market rally, depending on what uh NVIDIA uh says. If uh if
- 7:52
- Unidentified speaker (speaker_1): you know tech stocks decide to sell off again uh tomorrow, we could get uh another uh another another shakeout, shake out uh, but all all of uh the selling is eventually gonna pay. pave uh pave the way for a new round of uh of buying. So at this point it's really just a matter of uh waiting for that first day of a rally attempt uh uh and then again just waiting for
- 8:12
- Unidentified speaker (speaker_1): for confirmation of a of a new rally. So um you know, more selling on the S P five hundred uh today and uh at least it uh it made a it it you know made a stand at a at a longer term uh support level today.
- 8:26
- Alyssa Koram: Mm-hmm. So holding the two hundred A for now, can that continue? So tomorrow's gonna be pretty critical. And like you said, Nvidia could have a a lot to do that with that. We're keeping an eye on uh headlines uh related to the earnings report, but we'll circle back to that at the end of the show.
- 8:43
- Unidentified speaker (speaker_1): SP
- 8:44
- Unidentified speaker (UNKNOWN): uh I was
- 8:44
- Unidentified speaker (speaker_1): just gonna say SP only seven percent off its high, uh less than uh like I said, Nasdaq has pulled back about three thirteen and a half percent off its high. SP uh only about half of that, about seven percent uh at its low today, only about uh seven percent off its uh recent high. So much uh shallower pullback for the SP 500.
- 9:04
- Alyssa Koram: So far, hopefully
- 9:05
- Unidentified speaker (UNKNOWN): it stays that way.
- 9:07
- Alyssa Koram: We wanna we wanna see a turnaround here, but we'll we'll uh uh hope for the best, prepare for the worst, right,
- 9:12
- Unidentified speaker (UNKNOWN): Ken?
- 9:13
- Unidentified speaker (speaker_1): Exactly.
- 9:13
- Alyssa Koram: Okay. Let's go to the Dow. Here's blue chips uh below the two hundred day line. So the decline here, one point six percent. That does put it uh really close once again to the two hundred day. So it looks like today the two hundred day at fifty seven seven seven, it did close at fifty seven six one. So
- 9:33
- Alyssa Koram: gotta get your magnifying glass out, but it did close below the two 200 hundred day.
- 9:37
- Unidentified speaker (speaker_1): Yeah, uh pretty close to a a test here, maybe just a a little bit of a close below the 200 day, but uh very similar to the SP five hundred again, an undercut uh from that uh from that same low that the that the Nasdaq and the S P five hundred undercut uh as well here. So pretty much uh a test for the uh for the Dow Jones uh
- 9:57
- Unidentified speaker (speaker_1): industrial. This is where a lot of the damage was in in the market uh today, just when you thought that kind of blue chips. were were kind of a safe haven and you know people were hiding in uh a lot of these uh blue chip uh safer names. But uh you know, a lot of the selling in the market today, not so much in chip stocks and uh AI stocks. There w there were still selling in in these names uh
- 10:17
- Unidentified speaker (speaker_1): today, but it was software stocks that really uh was the focal point of the the selling uh today. IGV materially underperformed uh the SMH and uh you know chip stocks in general. IG V was uh what was the percentage decline there?
- 10:34
- Unidentified speaker (UNKNOWN): Three point three percent yeah
- 10:35
- Unidentified speaker (speaker_1): three point three so that was uh really double uh what uh what the uh what the SMH uh did today. So it did a lot worse than uh the uh the chip uh ETF. And then when you look inside the the the Dow, um, you know I mean Salesforce really, really took a beating today. I mean, this was a a nine percent uh at one
- 10:55
- Unidentified speaker (speaker_1): point it was a nine percent uh decline for uh for Salesforce. And uh it wasn't just Salesforce that uh was uh was weak uh in in in the Dow.
- 11:06
- Unidentified speaker (UNKNOWN): Uh
- 11:06
- Unidentified speaker (speaker_1): you had uh let's see, it was uh Nike uh took uh took a big hit in the Dow today. A lot of your health insurers led by uh United Health, U. UNH was uh was down big in the in the blue chip index, uh IBM, uh you had Home Depot, I believe, which had uh earnings. So a lot of blue chip names uh really uh really hit
- 11:26
- Unidentified speaker (speaker_1): hard uh today. Yeah, Home Depot had earnings and that uh sold off down to its uh twenty one day moving average. So a lot of blue chip names under pressure uh today uh as well.
- 11:36
- Alyssa Koram: Mm-hmm. Okay, good color. there. And we'll take a quick look at small cap. So fresh lows here going back to the early October time frame and seeing continued weakness in small cap land as well.
- 11:53
- Unidentified speaker (speaker_1): Yeah, that uh 50 day moving average on a pretty sharp uh downtrend, uh the 200 day line that Uh you can see those moving averages are are are crossing. So this has really been a lagging uh index for for you know for quite
- 12:06
- Unidentified speaker (UNKNOWN): some
- 12:07
- Unidentified speaker (speaker_1): quite some time. But uh yeah uh uh uh small cap index undercut that uh 200 day line a while ago. And uh yeah, it's pretty far off highs here and uh still you know gonna gonna wait for day one of a rally attempt uh here too. But this one has uh really been been hit hard and uh yeah, we'll just uh keep
- 12:27
- Unidentified speaker (speaker_1): an eye out for for day one here too as well.
- 12:30
- Alyssa Koram: All right, and let's also check in on RSP. We've been talking about how the equal weighted S P 500 ETF has been holding up better uh versus some of the other indexes. So we didn't get an undercut of the low, the previous short-term low from 11.6, eleven six, uh but we're right there.
- 12:51
- Alyssa Koram: above the 50-day line and the decline here 1.4%.
- 12:56
- Alyssa Koram: So it's not like uh we're seeing all stocks immune to this. You know, we're we saw a worse decline here for RSP than SPY today.
- 13:08
- Unidentified speaker (speaker_1): Yeah, I mean, this is a pretty bad break for RSP today. I mean, this is uh an ETF that 10 tend you do you tend not to see really. you know, violent whippy moves in uh in RSP, but you can see the bar today. This was a a pretty bad break of the the twenty-one day line and uh a pretty big uh spread uh from the intraday high
- 13:28
- Unidentified speaker (speaker_1): and the low stopped uh just above the fifty day moving average. But when you get uh four to one, you know, four to one negative uh breadth on the uh on the uh on the NYSE uh you
- 13:38
- Unidentified speaker (UNKNOWN): know
- 13:38
- Unidentified speaker (speaker_1): not not surprising to see this uh uh to see this move uh like it did today. So, you know, down down uh well over uh one percent. Held support at the at the 50 day, but uh yeah, not great uh not great uh breadth uh today and the equal weighted uh RSP, you know, pretty big uh percentage decline. Support held, but um looking uh
- 13:58
- Unidentified speaker (speaker_1): looking looking weak today.
- 14:01
- Alyssa Koram: Yeah. Okay. And uh we'll get your thoughts, Ken, on the 10 year here. What should traders be looking for and how should they be interpreting the recent action?
- 14:12
- Unidentified speaker (speaker_1): Well we're gonna get the Fed minutes uh tomorrow on Wednesday. Sometimes that's a a market mover, sometimes uh it it's not. Uh obviously the the the uh eyes are on the the Fed meeting in uh in uh December. Uh you know, the Fed is mostly. pr most likely gonna be hiking rates uh by a quarter point. At one point there was, you know, maybe
- 14:32
- Unidentified speaker (speaker_1): uh very small talk of a of a fifty basis point uh hike, but uh most likely it's just gonna be a a a a quarter point hike and uh and we will uh we will see uh we'll we'll we'll see what comes of that. Uh interest rates were down today. We had retail sales uh for October that was released uh before the open
- 14:51
- Unidentified speaker (speaker_1): Uh the headline number was in line, uh excluding autos. You had a pretty good number that was better than uh expected uh uh expected, excluding autos. Sales were up six tenths of a percent. That was uh better than the four tenths of a percent uh expectations. But instead uh instead of rates uh going up on that number, they actually uh
- 15:11
- Unidentified speaker (speaker_1): backed off a little bit. And uh so you saw the ten year yield uh come in a little bit, which was maybe a little bit of a surprise, but again, you saw the yield up for several days in a row uh ahead of today. So maybe just uh a little bit of uh just a little bit of uh backtracking here. So uh we'll see what the Fed minutes uh say tomorrow. I
- 15:31
- Unidentified speaker (speaker_1): think the focus is probably gonna be more on NVIDIA than the uh Fed minutes, but you never know. The minutes will be r released at uh two PM uh Eastern uh Eastern time on uh on Wednesday. And uh we'll see what uh we'll see what what what what comes of it.
- 15:47
- Alyssa Koram: Mm-hmm. And then two more sectors to check out before we move on. Financials down one point nine percent on the day, and then healthcare. Here's XLV down one point four percent on the day. So thoughts. on the performance of these sectors?
- 16:05
- Unidentified speaker (speaker_1): Yeah, well it was not surprising to I mean the financials uh with the 10-year yield down, uh not surprising to see financials uh lagging. And uh maybe they're a little bit nervous ahead of the uh the Fed minutes uh tomorrow, but uh XLF was uh was the worst performing SP S P five hundred uh sector today. And uh
- 16:25
- Unidentified speaker (speaker_1): yeah, XLV uh not not far behind. I mentioned uh the health insurers were were were pretty pretty weak today, whether it was uh uh Centeen or or uh UNH uh in in the in the Dow, Humana. Uh they were all kind of weak uh across the board. I think the the the
- 16:45
- Unidentified speaker (speaker_1): government is taking s uh steps to curtail fraud uh in in this uh area so a lot of these uh stocks in this group were were were down. Not uh not uh not sharply, but you know, Humana was down but uh kind of closed in the middle of its range and held at the ten day moving average. So some
- 17:05
- Unidentified speaker (speaker_1): s some percentage uh declines in the group, but uh not too much uh damage done uh technically to Humana.
- 17:12
- Alyssa Koram: Yeah. All right. Well you talked about the weakness in the software sector today. One that's holding up overall, even though it was down on the day, is PACOM. Shares were down 2.7% on the day, but still holding above the 50-day line and in an uptrend
- 17:31
- Alyssa Koram: going back to this summer. So not a whole lot of stocks can say the same right now, Ken.
- 17:37
- Unidentified speaker (speaker_1): Yeah. I you know I mentioned this one yesterday on uh on IBD Live. I thought I might have mentioned it uh on a on a prior video, but I I uh I mentioned it on IBD Live yesterday just because I think these workforce uh management uh stocks are are acting well and uh you know PACOM had a recent uh breakout and then it uh it it came down to its fifty 50-day day moving
- 17:57
- Unidentified speaker (speaker_1): average after reporting earnings and it was a volatile reaction to uh to earnings earnings, but it uh it it closed uh kind of in the middle of it of its range after it uh after it initially sold off and uh ultimately found support at its 50-day moving average and then kind of moved uh moved off the the 50-day line and and
- 18:17
- Unidentified speaker (speaker_1): found support and kind of moved back into a buy zone. And I just thought it was interesting on a really bad day for a lot of stocks in the enterprise uh software group. and again it was it was led by uh by by Salesforce that was down some nine nine percent that kind of bled into a lot of other software stocks and you know Paycom was
- 18:37
- Unidentified speaker (speaker_1): uh was down uh was down a little bit but uh after several updates in a row I thought it uh I thought it managed its decline uh you know pretty pretty well today. And it really is just still sitting in a in a buy zone here from uh from that uh from that last uh buy point and I think it still looks pretty uh pretty healthy here and it's in a you know it's in a
- 18:57
- Unidentified speaker (speaker_1): good uh industry group inside of the enterprise software group, these workforce uh management, human resource uh payroll type uh software uh firms that basically manage uh the the back end for for companies are are are really doing well. There's uh really broad based uh strength
- 19:17
- Unidentified speaker (speaker_1): inside this area of enterprise software. Uh paylocity and other other stocks are just doing uh very, very well here. So I think Paycom is uh a good name to uh to to to to keep an eye on here. It's just a a good institutional quality name and sitting right in a buy zone here. And you know the the earnings report that they just uh
- 19:37
- Unidentified speaker (speaker_1): reported was uh was solid. and sometimes these stocks they're they're gonna sell off on earnings when the numbers are are good. You know, they just uh expectations are very high uh when they report earnings so sometimes there's a knee-jerk reaction but this one has uh has bounced back pretty pretty nicely post uh post earnings
- 19:56
- Alyssa Koram: all right one for the watch list next on our list let's go to ASN ASND. D and I think you're right Ken
- 20:03
- Alyssa Koram: We may not have covered this on the stock market today show very much, if at all, but I feel like we have brought it up on IEBD Live. I'm going to go to the weekly chart to look at this profitable biotech that's forming a double bottom base.
- 20:18
- Unidentified speaker (UNKNOWN): Yeah,
- 20:19
- Unidentified speaker (speaker_1): Ascendus is uh is really interesting. Um, done a little work on this uh company. It is a profitable uh biotech. Uh you can see the the earnings in coming quarters are gonna be a little bit lumpy, but the top line growth here is uh is really, really consistent. It's a big company, you know, sixteen, seventeen billion market cap. It's
- 20:39
- Unidentified speaker (speaker_1): very, very liquid. Uh take a look at the fund sponsorship too. This is a a company that's got uh outstanding Standing uh mutual fund uh ownership. It's got some nice uh uh nice funds, I believe. from the uh mutual fund index in there. Uh this company has a drug uh delivery uh technology uh that's referred to as
- 20:59
- Unidentified speaker (speaker_1): transcon. So it's uh it's basically used to extend how long uh a medication stays active inside the body. So uh they uh are work in areas like oncology and they also are very big in uh pediatric
- 21:18
- Unidentified speaker (speaker_1): pediatric growth hormone uh deficiency so uh the way that they deliver uh the drugs inside the body is very unique it makes them uh kind of unique in their in their business model but you can see they're generating a lot of revenue and uh and they're also uh they're also profitable and uh stock has been
- 21:38
- Unidentified speaker (speaker_1): spent just trending trending steadily higher and uh you know it's having a good week so far this week after you know many up weeks in a row. You see that uh see that that red bar this week it's just kinda holding holding tight after uh after a a really m multiple up weeks uh in a row so it's
- 21:58
- Unidentified speaker (speaker_1): just kind of sitting here and uh it doesn't have a healthy market work working in its favor. So that's uh that's a that's a yellow flag. But um you know this is a a profitable biotech with a very interesting you know drug delivery technology that's making money and uh it's got good fund sponsorship. So it uh you
- 22:17
- Unidentified speaker (UNKNOWN): know
- 22:17
- Unidentified speaker (speaker_1): checks a lot of boxes. It's got a good relative strength line. So uh at least a a company to you know maybe do a little more work on and uh look at some recent earnings reports. But um I think the the technicals look pretty good here.
- 22:30
- Alyssa Koram: Mm-hmm. Yeah, and uh really nice growth recently. Let's go to another biotech, TGTX.
- 22:39
- Alyssa Koram: This one
- 22:41
- Alyssa Koram: on our radar as well. It's in the same industry group. Pretty outstanding relative strength line on this one, Ken.
- 22:49
- Unidentified speaker (speaker_1): Yeah, this is uh this is one that uh we've we've uh I don't know, but we probably talked about this one on SM SMT uh off and on. Uh this has been in our database uh very profitable for um well off and on, but TG uh therapeutics has uh their their main, you know, uh commercial
- 23:09
- Unidentified speaker (speaker_1): drug is called Briumvi, which uh treats uh adults with relapsing form. forms of multiple sclerosis and it is approaching one billion dollars in annual revenue. So it's a it's a big blockbuster uh for them. And uh here you can see uh a big earnings uh
- 23:29
- Unidentified speaker (speaker_1): breakout and uh what I like here is just kind of this uh low volume kind of pullback and it's getting close to pulling back into the the buy zone here from uh from the uh from the prior breakout and as it uh as it pulls back now it's kind of pulling back to the ten day moving average and if the market, you know, just continues to
- 23:49
- Unidentified speaker (speaker_1): pull back here, this could pull back down to that twenty one day line and just just watch for a continued low volume pullback here. And if it if it comes back and tests that that twenty one day line, that's basically gonna be a a pullback and and test of that uh that prior buy area. So I like the look of the pullback here. It was a really powerful uh
- 24:09
- Unidentified speaker (speaker_1): earnings uh breakout and um you know the the pullback looks uh looks very orderly right now and any time a stock breaks out in heavy volume and you know the way that the market has been acting to see this stock pulling back in orderly fashion like it is this is uh pretty pretty impressive because we've had some
- 24:29
- Unidentified speaker (speaker_1): pretty ugly down days in the market, and uh this one has just been kind of pulling back fairly gently. So uh we'll see if it eventually tests that green line that tests that 21 day uh moving average. Uh yeah, this is a a really strong and leading um profitable biotech. I suspect it could try to find support at
- 24:49
- Unidentified speaker (speaker_1): that twenty-one twenty one day line and uh maybe give a a little bounce and uh alternate uh entry. So keep an eye on T G Therapeutics. It's another institutional quality biotech with great great sponsorship, great top line growth and uh you know, it's a uh a good solid name.
- 25:06
- Alyssa Koram: Yeah. All right, Ken, while NVIDIA earnings are out, we'll give the headline numbers and the stock reaction.
- 25:15
- Alyssa Koram: Stock, of course, badly beaten down in recent weeks, uh, even before the election, AI fears, and then the CEO exit news. But at any rate, the stock up about three percent right now in its first earnings report post Jensen won, beating on both the top and bottom
- 25:35
- Alyssa Koram: lines. And the outlook, I believe, was also.
- 25:39
- Alyssa Koram: positive, Ken. So obviously, you know, this result was what it was going to be with Jensen still there. Now he's not. So I think from now on, uh it's gonna come down to the call. Is there gonna be anything that analysts ask or pick up on or that
- 25:59
- Alyssa Koram: executives say that's going to move the stock.
- 26:03
- Unidentified speaker (speaker_1): I think it's going to be uh maybe one of the most listened to conference calls in in in recent quarters. There's no doubt about it. And uh, you know, Colette uh Kress is uh gonna be leading the call, who's the interim CEO. She's been, you know, the longtime CFO at NVIDIA, very,
- 26:23
- Unidentified speaker (speaker_1): very uh respected uh C level executive at uh NVIDIA. So um she'll do a great job and uh but it it is gonna be a a a very uh very closely watched uh conference call and they'll be yeah they'll be making a a lot of comments about uh I'm sure uh chip uh
- 26:43
- Unidentified speaker (speaker_1): chip shipments to to China and China business and all sorts of uh all sorts of things that are gonna be on analysts' uh minds. So um we'll just have to we'll have to listen and uh watch how the stock uh trades tomorrow. But it's certainly encouraging to uh yeah, I again I think people were expecting another really good
- 27:03
- Unidentified speaker (speaker_1): quarter. And uh I think uh you know people are probably expecting to hear, you know, good things about demand going forward. There's there's gonna come a time when Nvidia's, you know, gonna stop talking. about you know huge demand. I mean, eventually that will happen, but um
- 27:20
- Unidentified speaker (UNKNOWN): you know,
- 27:20
- Unidentified speaker (speaker_1): we'll we'll we'll see what they're they've been talking uh in recent earnings reports about you know still strong demand uh going out, and that that could be the case uh uh this time around too. So we'll just uh listen to what uh what they have to say. And uh
- 27:35
- Unidentified speaker (UNKNOWN): who
- 27:36
- Unidentified speaker (speaker_1): knows? We we could uh we we could see a very, very strong first day of our of a rally attempt uh tomorrow. It could be a volatile day for NVIDIA. Uh we'll we'll see what uh tomorrow tomorrow brings. But we're still kind of at a unsettled uh market here, but uh tomorrow should be interesting.
- 27:53
- Alyssa Koram: Yeah, tomorrow will definitely be interesting. We'll be watching and breaking it all down on IEBD Live in the morning. Thanks, Ken. We appreciate it.
- 28:03
- Unidentified speaker (speaker_1): Okay. You got
- 28:04
- Unidentified speaker (UNKNOWN): it.
- 28:05
- Unidentified speaker (UNKNOWN): So
- 28:05
- Alyssa Koram: speaking of IEBD Live, we hope you tune in starting 10 minutes before the opening bell, investors.com/slash IEBD Live for all the details on our daily morning live stream. We'll see you there. And then we'll also see you right back here tomorrow after the close.
- 28:37
- Alyssa Koram: This show is for informational and educational purposes only, and nothing should be construed as a recommendation to buy, hold, or sell any securities. Any securities that investment strategies discuss discussed may not be suitable for all investors. Make sure to consider consulting with your financial advisor before. making investment decisions.
More from Stock Market Today With IBD
Defense Key As Stocks Lose Ground; Humana, Appian, Sezzle In Focus
Episode discussion: Market indexes break key technical levels prompting defensive cash positioning; Humana, Appian, Sezzle analyzed
Speakers’ claims: Alyssa Corum and Justin Nielsen report that major US equity indexes, including the Nasdaq Composite and S&P 500, declined significantly on November 16, 2026, breaking below the 21-day and 50-day moving averages. Justin Nielsen advises raising cash and avoiding trend-following strategies, noting that the previous follow-through day signal was suspect due to low volume and failed confirmation. While defensive sectors like staples and utilities showed relative strength, they failed to sustain gains, and Bitcoin's decline signaled broad risk-off sentiment. The hosts highlight Humana, Appian, and Sezzle as relative strength outliers but caution against chasing gains in a weak market environment.
Indexes Vulnerable At Key Levels; Toast, Docusign, Crocs In Focus
Episode discussion: Speakers analyze market technicals near 200-day moving averages and review Toast, DocuSign, and Crocs charts.
Speakers’ claims: Speakers analyze the NASDAQ Composite, S&P 500, and Russell 2000 closing below or near their 200-day moving averages, noting the NASDAQ 100's 1.2% decline. They emphasize the 200-day line as a critical psychological and technical threshold for market sentiment. Speaker 2 identifies a follow-through day on the NASDAQ, defined by higher volume and price recovery, which signals a shift from defensive to offensive trading. The discussion shifts to individual mega-cap stocks, noting Google's weakness, Apple's stability, Microsoft's firming near the 50-day average, and Meta's potential base formation. Speaker 2 owns Toast, DocuSign, and Crocs, citing strong fundamentals and technical patterns, but warns of overhead resistance.